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New directions in antimalarial target validation
Fernando A. Batistaa,b, Benjamin Gyaua, Juliana F. Vilachaa, Soraya S. Boscha,b, Sergey Luneva, Carsten Wrengerb*
and Matthew R. Grovesa*
aStructural Biology Unit, XB20 Drug Design, Department of Pharmacy, University of Groningen, Groningen, The Netherlands; bUnit for Drug
Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
ABSTRACT
Introduction: Malaria is one of the most prevalent human infections worldwide with over 40% of the
world’s population living in malaria-endemic areas. In the absence of an effective vaccine, emergence of
drug-resistant strains requires urgent drug development. Current methods applied to drug target
validation, a crucial step in drug discovery, possess limitations in malaria. These constraints require
the development of techniques capable of simplifying the validation of Plasmodial targets.
Areas covered: The authors review the current state of the art in techniques used to validate drug
targets in malaria, including our contribution – the protein interference assay (PIA) – as an additional
tool in rapid in vivo target validation.
Expert opinion: Each technique in this review has advantages and disadvantages, implying that future
validation efforts should not focus on a single approach, but integrate multiple approaches. PIA is
a significant addition to the current toolset of antimalarial validation. Validation of aspartate metabo-
lism as a druggable pathway provided proof of concept of how oligomeric interfaces can be exploited
to control specific activity in vivo. PIA has the potential to be applied not only to other enzymes/
pathways of the malaria parasite but could, in principle, be extrapolated to other infectious diseases.
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Malaria remains a devastating global parasitic disease. There
were an estimated 219 million cases and 435,000 related
deaths in 2017 [1]. From the six Plasmodium species capable
of causing human malaria; Plasmodium falciparum and
Plasmodium vivax pose the greatest global health threat.
The former is prevalent in Africa, disproportionately
accounting for most malaria cases and deaths globally,
whereas the latter is a temperate zone parasite [2].
Currently, the only approved vaccine against malaria is
RTS, SA/AS018 [3]. Although this approach has an efficiency
of 39% in infants aged 5–17 month after 4 injections/treat-
ments, this rate is still precarious in a global scenario [4].
Moreover, Plasmodium is known to develop strategies in
evading the immune system when challenged with vaccines
over time [5].
Artemisinin-based combination therapies (ACTs) are cur-
rently the most effective frontline therapies against
P. falciparum [1]. These became a potent solution to pre-
viously acquired resistance to drugs such as sulfadoxine/
pyrimethamine and chloroquine in the mid-1900s [6].
Unfortunately, drug-resistance to artemisinin and its deriva-
tives has emerged in Southeast Asia [7]. This highlights the
need for constant basic research into the life cycle and
metabolism of P. falciparum in order to identify areas of
vulnerability in the parasite. Once new targets are identified
and validated, they can be used to generate new therapeu-
tics that uniquely target the malaria parasite.
Blood-stage proliferation of the malaria parasite in
humans is critically dependent on specific metabolites, and
their survivability is believed to be tightly dependent on the
availability and metabolism of carbon nutrients. Although
many key enzymes in carbon metabolism and related path-
ways could represent potential drug targets, the target-
validation process is far from simple, partly owing to the
complex nature of the parasite life cycle [8]. This complexity
has led to limited number of tools to properly validate
antimalarial targets [9]. Current efforts with genetic
approaches, small molecules, and siRNA tools among many
others as antimalarial validation probes have shown signifi-
cant limitations. These constraints call for new innovative,
highly specific validation tools [10]. This review is therefore
aimed to explore the pros and cons of the tools that are
currently used in the validation of potential antimalarial
targets. A spotlight is placed on our recent contribution to
the field, the use of the Protein Interference Assay (PIA) as
a validation probe. PIA exploits a common feature of most
protein complexes – oligomerization –, an shared phenom-
enon seen in all organisms, present in one- third of all
protein structures currently available in the Protein Data
Bank (PDB) [11,12] and shared by key enzymes of the meta-
bolic cycle of P. falciparum [5].
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2. Currently employed antimalarial drug target
validation tools
Rational drug discovery mostly begins with novel target identi-
fication followed by experimental target validation steps, and
assessment of molecular druggability [13]. Target identification
is, nowadays, a more easily achievable process than it was two
decades ago [14,15]. With the advent of the Human Genome
Project and rapid screening technologies, an large number of
potential targets associated with most physiological processes
have emerged. Drug target validation, on the other hand,
remains a very challenging process. From a rational drug design
perspective, target validation is a merit-based assessment of
a molecular target for therapeutic applications. It addresses
whether the target of interest is functionally involved in the
cause of a disease and its associated symptoms [14] and thus, its
suitability for target-based drug research. This ‘validation of
essentiality’ is hinged on, among other factors,
a comprehensive understanding of the disease pathophysiol-
ogy and the target’s mechanism of action, as well as its network
of interrelated pathways [16]. However, it is important to
remark that, by definition, a therapeutic target is only fully
validated if a therapeutic benefit with an acceptable safety
window is provided [17]. This review is focused on the valida-
tion of essentiality as a starting point for target-based drug
discovery rather than the final target validation.
Our group have recently published a manuscript that lists
new potential antimalarial targets [18]. The list, which aims to
avoid the the propensity of the research communities to focus
on a small fraction of the proteome (a phenomenon known as
the ‘Harlow-Knapp effect’[19]), includes, for instance, compo-
nents of the mitochondrial electron transport chain (ETC),
tricarboxylic acid (TCA) cycle and pyrimidine biosynthetic
pathway. All the target candidates mentioned in this publica-
tion would benefit from validation studies that could unveil
their possible essentiality and consequent potential as thera-
peutic targets.
Differently from rational target-based drug discovery, anti-
malarial development often starts from the identification of
compounds screened against the blood stages of
P. falciparum. The screening of large compound libraries,
known as phenotypic screens, may revolutionize the drug
discovery process. More than 6 million compounds have
already been tested against P. falciparum, and about 0.5% of
these compounds presented an EC50 lower than 1µM [20–22].
In fact, rational drug design can be considered more an excep-
tion than the rule when it comes to antimalarial drug discov-
ery. According to information available in the literature, all the
currently approved antimalarial drugs were not developed in
a fully rational manner. These drugs resulted from in animal or
in vitro model studies (e.g. phenotypic screens) instead of
studies focusing on the inhibition of known, validated targets.
Thus, the mode of action of the identified molecules, as well as
the mechanisms of emergence of resistance, are often not
fully understood [23,24]. The identification and validation of
the enzymes and pathways affected by these molecules could
reveal the mechanisms by which resistance arises and/or allow
for further medicinal chemistry optimizations [25]. Therefore,
the importance of the validation process remains. For exam-
ple, the identification of genetic mutations that mediate drug
resistance with subsequent validation has proved to be
a successful route to target malaria [26,27]. Mutational analysis
of P. falciparum under drug pressure has revealed insights into
mechanisms of resistance of most of the commonly used
antimalarials, such as chloroquine [28,29], amodiaquine [30],
piperaquine [31,32], DHFR inhibitors [33], sulfa drugs [34,35],
lumefantrine [36], mefloquine [37], clindamycin [38], atova-
quone [39,40] and artemisinin compounds [41,42]. Resistance
mechanisms against the 4-aminoquinolines compounds pri-
maquine and tafenaquine, the antibiotic doxycycline and the
aryl amino-alcohol compound quinine remain unclear [26]. For
P. vivax, the scenario remains relatively precarious, with
genetic mediators of resistance fully reported only for DHFR
inhibitors [43], sulfa drugs [44] and the aryl amino-alcohol
compounds lumefantrine and mefloquine [45]. The unveiling
of resistance mutations and the changes caused by these
mutations, enabled by the development of sequencing and
gene editing techniques described below, allows for a deeper
understanding into why particular treatments fail and sup-
ports the design of more effective antimalarial therapies.
There are several conventional tools for antimalarial target
validation. These are dominated by genomic approaches
which seek to either knock-in or out of a particular gene that
encodes for an essential protein in the life cycle of the parasite
[10]. Knockdown via conditional and inducible gene expres-
sion tools have also taken center stage in an effort to validate
enzyme essentiality in Plasmodium, especially in instances
where a complete knockout is undesirable [46]. Controlling
protein activity at the RNA level with transcript interference
and degradation tools has also led to a considerable improve-
ment in target validation. Proteomic approaches have been
developed to overcome shortcomings associated with geno-
mic tools unable to deal with the functionally different iso-
forms of RNA transcripts [14]. The pros and cons of the
currently employed antimalarial validation techniques are dis-
cussed below.
2.1. Genomic techniques
Genomic modification techniques, sometimes referred to as
‘reverse genetics’, employ the principle that the physiologi-
cal function of a target protein could be validated by
Article highlights
● The malarial parasite is a major threat to populations in the devel-
oping world and the emergence of multi-drug resistant strains
requires the development of new therapies.
● Developments in in vitro target validation in malaria have made
significant progress, but there remain pitfalls in each methodology
that should be borne in mind during the validation process.
● Potential validation techniques should be as specific for the drug
target as possible, with minimal cross-talk with other biological
systems.
● Disruption of oligomeric interfaces can be achieved by the introduc-
tion of mutant subunits in oligomeric protein complexes.
● Oligomeric PIA represents a valuable addition to the current valida-
tion toolbox and opens a new avenue for exploring metabolic path-
ways in drug target validation.
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manipulation of its gene expression [14]. Complete gene
switch on/off techniques, popularly termed as knock-in or
knockout, are commonly used to control protein function at
the DNA level. Genetic knockout validation, for example,
works on the assumption that the effect of administering
a highly specific target inhibitor could be precisely repli-
cated by gene deletion or disruption to halt expression
[47]. The use of reverse genetics techniques applied to
malaria started with the development of systems for both
transient and stable transfection of Plasmodium parasites.
These had to circumvent the initial difficulties found due
to the unstable A/T-rich DNA sequence and thick 4-mem-
brane enveloped nucleus of the parasites [35]. The genomic
techniques discussed below have been applied to the func-
tional analysis of many Plasmodium genes and gene pro-
ducts involved in erythrocyte invasion, sexual
differentiation and cytoadherence of infected erythrocytes
(Table 1).
2.1.1. Single and double crossover
A versatile system for the manipulation of the Plasmodium
genome is the stable transgene expression via homologous,
single crossover recombination. By the use of this technique,
parasites are transfected with plasmids designed to express
a transgene and a selectable marker. Successfully transfected
parasites are then isolated by positive drug selection. Within
the transfected parasites, crossover events potentially inte-
grate the episomal DNA within the parasite’s genomic DNA.
The selective drug is then removed from the culture for
3–4 weeks. The absence of the drug forces both integration
of the episomal DNA into the parasite’s genomic DNA and
removal of episomal DNA. Further positive reselection with the
drug eliminates the non-integrated forms of the parasite. This
cycle is repeated several times until the removal of all epi-
somes and isolation of integrated forms (Figure 1(a)) [57].
Thanks to parasite haploidy [46], a single crossover event
leads to knockout of parasites’ target genes. But despite the
advances brought by this method, it remains a long and
inefficient procedure, with a timeframe of approximately
12 weeks required to generate the transgenic parasite [10].
Moreover, the persistence of circular forms of the plasmid is
a major impediment for isolation of parasites with chromoso-
mally integrated copies of the plasmid [58]. In order to cir-
cumvent these limitations, the double crossover approach was
applied to P. falciparum [59]. Similar to the single homologous
recombination, this method begins with transfection and posi-
tive drug selection. The cultures are then submitted to
a negative selection by the addition of a second drug.
During this step, parasites containing episomes are eliminated
due to increased sensitivity to the second drug (Figure 1(b)).
The increase of sensitivity occurs due to the presence of genes
such as thymidine kinase of Herpes simplex virus [60] and the
cytosine deaminase of Escherichia coli [61] in the transfected
construct. The products of these genes convert a normally
harmless metabolite (5-fluorocytosine and ganciclovir respec-
tively) into a toxic one. But although this technique increased
the potential for integration events and reduced the time to
obtain the selected parasite, it presents a ‘bystander’ effect
[62] which causes parasite death due to the presence of the,
theoretically, harmless metabolite in the culture even in the
absence of the episomal DNA [10].
2.1.2. Customized ZNFs
The use of customized zinc-finger nucleases (ZFNs) represents
a more modern approach for modulating the expression of
a target gene when compared to the single and double crossover
methods. In this technique, the transfection of parasites with
a construct that encodes for pairs of engineered zinc-finger pro-
teins linked to an endonuclease (Fokl) leads to endogenous
expression of these zinc-finger proteins [64]. After binding to
their target sequence on each side of the chromosome, the zinc-
finger proteins induce nuclease activity, causing a double-strand
break (DSB). This allows for alteration of the target DNA sequence
by taking advantage of the homology-directed DNA repair
mechanisms at the site of nuclease action [65] (Figure 1(c)). In
both P. falciparum and P. vivax, experiments have demonstrated
the generation of ZFN-mediated gene deletions, allelic exchanges,
and specific nucleotide alterations in the presence or absence of
selectablemarkers (Table 1). Recently, the use of ZFN gene-editing
enabled the characterization of the PfCRT resistant variant in
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Figure 1. Schematic representation of genomic validation techniques applied to Plasmodium. (a) Single crossover [57]. (b) Double crossover [59]. (c) Zinc Finger
Nucleases (ZNFs). The parasites are transformed with a construct that encodes for pairs of engineered zinc-finger proteins linked to an endonuclease. After
endogenous expression of the ZFNs (showed in the picture as ZFNL and ZFNR) the zinc finger proteins bind to their target sequence on each side of the
chromosome and induce nuclease activity, causing a double-strand break (DSB). This allows for alteration of the target DNA sequence by taking advantage of the
homology-directed DNA repair mechanisms at the site of nuclease action [64]. (d) Clustered Regularly Interspaced Short Palindromic Repeats-associated proteins
(CRISPR-Cas) system. The parasites are co-transfected with two plasmids; one contains the Cas9 nuclease gene, and the other contains the DNA fragment encoding
the sgRNA and the donor template DNA. After endogenous expression, Cas9 nuclease forms an RNA-protein complex with the sgRNA. Binging of the sgRNA to the
specific genomic locus induces Cas9 to perform a double-strand break (DSB) on the genomic DNA. Homologous recombination between the cleaved genomic locus
and a donor DNA present in the sgRNA construct leads to the integration of the latest to the genome [63,91].
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piperaquine-resistant P. falciparum isolates from Cambodia [66].
Another successful example of the use of ZFNs in target deconvo-
lution is the characterization of PI4K mutations that confer resis-
tance to the antimalarial compound class imidazopyrazines [67].
A disadvantage of this approach is the necessity of generation and
validation of a new set of sequence-specific ZFNs for each target,
which massively increases the cost of the technique [68,69].
2.1.3. CRISPR-Cas
The most recently developed technique in reverse genetics
applied to Plasmodium is the Clustered Regularly Interspaced
Short Palindromic Repeats-associated protein (CRISPR-Cas)
system [70]. This method, widely used in multiple organisms,
introduces DSBs through Cas9 endonuclease action guided by
a single guide RNA (sgRNA) strand (Figure 1(d)). Parasites are
co-transfected with two plasmids; one containing the Cas9
nuclease gene, and the other containing the DNA fragment
encoding the sgRNA and the donor template DNA. Within the
parasites successfully transfected with both plasmids (isolated
by positive drug selection), the Cas9 nuclease forms a complex
with the sgRNA which contains a sequence complementary to
the target gene. This complex binds to the specific genomic
locus via the sgRNA and then cleaves the double-stranded
DNA via Cas9. Homologous recombination between the
cleaved genomic locus and the donor DNA causes integration
of the latter to the genome [71–73]. Both gene editing and
directional knockout (in non-essential genes) have been
achieved using the CRISPR-Cas system (Table 1). The impact
of this revolutionary technique can be seen in recent studies
that enabled the mechanistic understanding of resistance to
antimalarial drugs and drug candidates. Ng et al. have
reported the resistance of blood-stage P. falciparum parasites
against a class of piperazine-containing compounds after suc-
cessful modification of the gene pfmdr1 [74]. However, this
modification promotes increase efficiency of artemisinin-based
combination therapy partner drugs [74]. White et al. have used
the CRISPR-Cas system to study resistance development
against the drug candidate DSM265. Five of the generated
point mutations in the binding pocket of the target protein,
dihydroorotate dehydrogenase (DHODH), have shown to
reduced potency of this compound to inhibit P. falciparum
growth, suggesting the necessity of a combinational therapy
even before the drug hit the market [75].
But while more accurate, faster and cheaper than conven-
tional and ZNF tools described above, the CRISPR-Cas method
possesses limitations. As described above, the most traditional
approach for the application of CRISPR-Cas in Plasmodium
parasites requires co-transfection with two plasmids [71–73].
This is necessary due to the absence in Plasmodium of the
error-prone non-homologous end joining (NHEJ) mechanism,
although present in human cells [76]. Instead, the malaria
parasites rely on the homologous mechanism [77]. The depen-
dence on whether the two plasmids co-exist in the parasite is
a limiting factor for the effectiveness of genetic modification
due to very low transfection efficiency in P. falciparum [78].
Aiming to overcome the double transfection limitation,
a P. falciparum cell line expressing the Cas9 nuclease (PfCas9)
was recently established [78]. This cell line makes use of
a centromeric plasmid, which segregates with high efficiency,
resulting in stable maintenance over multiple nuclear divi-
sions. Although a cell line which possesses the Cas9 nuclease
gene integrated into the genome is still to be developed, the
use of PfCas9 cell line has shown improved efficiency.
2.2. Conditional and inducible tools
In malaria, knocking out constitutive genes is often not ade-
quate in the analysis of functional targets with diverse activity
at different stages of parasite development [14]. The key to
control gene expression temporally and spatially lies in the
use of conditional and inducible approaches [79]. The use of
the DD/DDD, Tet-Off, riboswitch and Cre/FLP recombinases
systems in the generation of conditional knockouts/knock-
downs in Plasmodium is discussed below (Table 2).
2.2.1. DD/DDD
Conditional knockdown at protein level can be obtained by the
introduction of destabilizing domains to the protein of interest.
Integration of FK506-binding protein (FKBP)-based destabiliza-
tion domain (DD) [88] or an Escherichia coli DHFR destabilizing
domain (DDD) [65,89] in fusion with the target protein leads to
protein ubiquitylation and degradation by Plasmodium degra-
dation machinery due to instability of these domains. However,
this instability can be reversed by the addition of stabilizing
compounds (Shield 1 for DD fusion proteins and trimethoprim
for DDD fusion proteins), which allows for control of the expres-
sion at protein level. For the use of DDD fusion proteins, para-
sites must contain a human DHFR expression cassette in their
genome, which confers resistance to trimethoprim. Multiple
proteins from P. falciparum were analyzed by fusion with DD
while both P. falciparum and P. yoelii were subjects of study by
DDD fusion approach (Table 2). The use of DD fusion protein
has recently validated essentiality of the P. falciparum
Merozoite Organizing Protein (PfMOP). Induction of PfMOP
degradation resulted in inner membrane complex formation
defect, causing maturation arrest with aberrant morphology
and parasite death [90]. But although powerful, the use of
destabilizing domains is limited by protein location, since pro-
teins that are secreted are not targeted by the protein degrada-
tion machinery of the parasite and thus cannot be targeted via
this approach [91].
2.2.2. Tet-OFF system
Transcriptional knockdown with the anhydrotetracycline (ATc)-
inducible system provides inducible and conditional transgene
expression at a defined stage and time [92]. In this approach, the
parasites are transfected with a construct containing a gene that
encodes for a transcriptional transactivator domain (TRAD). Via
homologous recombination, the TRAD is integrated into the
genome of the parasite and placed under the transcriptional
control of the target gene promoter, while the expression of
the target gene will be controlled by an inducible minimal pro-
moter (tetracycline operator – TetO). The binding of expressed
TRAD to the inducible promoter (TetO) and consequent induc-
tion of the target gene expression ismediatedbyATc. Addition of
ATc to the culture leads to inactivation of TetO through the
inability of the TRAD to bind the operator, halting transcription
of the target gene in a controlledmanner (Figure 2(b)). Activation
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or repression of P. berghei’s blood stage essential genes have
been performed via this approach (Table 2). The disadvantage
here is that the tet-OFF system is not fully functional in the
generation of conditional knockouts in P. falciparum, the most
lethal parasitic form, possibly due to lack of efficiency of the TRAD
at recruiting transcription factors in this species [10,91]. However,
the use of the TetR (tetracycline repressor) domain, which is part
of the TRAD, has been successfully reported in an alternative and
recently describedmethod that achieves conditional knockdown
by combining the (ATc)-inducible system and RNA aptamers
[93,94]. Successful examples of target candidates that had their
essentiality validated by this method include the protease plas-
mepsin V [95], the nutrient-permeable channel EXP2 [96], and the
Niemann-Pick type C1-related protein [27].
2.2.3. Riboswitch system
A valuable approach for the generation of inducible gene
knockdowns is the use of the riboswitch system. This techni-
que makes post-transcriptional regulation possible by the use
of the self-cleaving GlmS ribozyme [97,98]. This RNA molecule,
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Figure 2. Schematic representation of conditional/inducible validation techniques applied to Plasmodium. (a) Post-translational knockdown principle in Plasmodium.
Integration of FK506-binding protein (FKBP)-based destabilization domain (DD) or an Escherichia coli DHFR destabilizing domain (DDD) in fusion with the target
protein leads to protein degradation by Plasmodium degradation machinery when stabilizing compounds are removed from the culture [65,89]. (b) Tet-OFF system.
Integration of episomal DNA upstream the target gene introduces a transcriptional transactivator domain (TRAD) gene sequence and an inducible promoter (TetO).
In the absence of Anhydrotetracycline (ATc), the expressed TRAD binds to the inducible promoter, stimulating the mRNA expression of the target gene. Addition of
ATc prevents binding of the TRAD to the TetO promoter reducing the expression of the target gene [92]. (c) Riboswitch system. Integration of Glms coding sequence
to 3ʹUTR of target gene coding sequence leads to degradation of its transcribed mRNA in the presence of glucosamine-6-phosphate (GlcN) due Glms ribozyme
activity [97,98]. (d) Conditional knockout. Recombinase target sequences (loxP for Cre recombinase and frt for FLP recombinase) are integrated to the endogenous
locus flanking the target gene coding region. The conditional expression of the recombinase encoded by the transfected construct or induction of diCre dimerization
results in recombination of the two loxP or frt sites leading to target gene sequence excision [101,102].
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in the presence of the inducer glucosamine-6-phosphate
(GlcN), can perform cis-cleavage of the mRNA into which
they are integrated thereby reducing protein levels [97–99]
(Figure 2(c)). The use of this system has been successfully
reported in the assessment of multiple P. falciparum genes
and is currently the method of choice for the generation of
inducible knockdowns in malaria (Table 2). For example, a very
recent study applied the riboswitch system in the conditional
disruption of cyclic AMP signaling pathway components and
reported adenylyl cyclase beta (ACβ) and its downstream
effector, cAMP-dependent protein kinase (PKA) as critical for
RBC invasion [100]. But although highly promising, this tech-
nique has as a disadvantage the fact that prolonged exposure
of parasites to high doses of GlcN can cause cytotoxic
effects [98].
2.2.4. Cre/FLP recombinases
Conditional deletion of gene loci can be achieved by expres-
sion of recombinase enzymes such as Cre or site-specific
recombinase FLP. These enzymes can trigger the excision of
genetic sequences by recombining two target sequences that
flank the region to be excised [101,102] (Figure 2(d)). The
conditional expression of these enzymes, by systems like the
tet-OFF described above, allow for conditional knockout of
Plasmodium essential genes. Initial studies using Cre recombi-
nase, which recognizes loxP sites, have shown low efficiency
when combined with a Tet promoter in P. falciparum, while
FLP, which recognizes frt sites, provided better results [65,103].
However, the more recent development of a split diCre pro-
tein, which can be induced to dimerize into a functional
enzyme by the addition of the ligand rapamycin, has provided
control of the expression levels in a more precise manner
[104]. A recent example of successful application of this tech-
nique includes the study of genes involved in a protease
cascade proved to regulate the release of P. falciparum para-
sites from host red blood cells [105]. The conditional knockout
of the serine protease SUB1 by diCre caused the parasites fail
to rupture the parasitophorous vacuole and preventing the
continuation of P. falciparum replication cycle [105]. This
approach possesses the advantage of providing conditional
knockout of Plasmodium blood-stage essential genes, with
complete ablation of gene function if the gene is excised,
but since the excision does not occur in 100% of parasites,
the difficulty in distinguishing parasites which gene excision
has occurred represents its main downside [91].
2.3. Proteomic approaches
As many gene products have slightly different functional iso-
forms with further post-translational variations, validating tar-
gets at genetic level can be problematic. Arguably, the best
approach would be, instead, to perturb the function of the
protein of interest [14]. Proteomic validation tools are there-
fore the ideal in most instances, more so because the majority
of developed drugs target specific proteins and not their gene
precursors. Although these tools have the advantage of being
applicable to parasite essential proteins, structural information
of these targets is often required [8]. Here, we discuss the use
of aptamers, small molecule validation tools, and our recent
contribution – the use of protein interference assay as a new
and highly specific tool in the validation of antimalarial target
candidates (Table 3).
2.3.1. Aptamers
Aptamers are single-stranded RNA (ssRNA) or single-stranded
DNA (ssDNA) oligonucleotides whose unique three-
dimensional structure enables them to interact with a specific
target [65]. The use of aptamers, also known as Systematic
Evolution of Ligands by Exponential Enrichment (SELEX), consists
of incubation of a random nucleic acid library with the target
culture/lysate followed by isolation of target-bound aptamers
and amplification of these aptamers using conserved primer
sequences for further rounds of selection [107,108] (Figure 3
(a)). The use of negative selection, in which aptamers that do
not recognize an alternative target are kept while those that do
are discarded, improves the specificity of the selected aptamers
and enables the design of a personalized strategy [109].
Although most of the studies that have made use of aptamers
in malaria were focused on diagnosis, this technique has poten-
tial both in antimalarial target identification/validation and in use
as therapeutic molecules [110]. As mentioned above, the
recently developed TetR–DOZI–aptamer system combines RNA
Table 3. Proteomic approaches applied to antimalarial target validation.
Technique Principle
Examples of successfully
assessed targets Pros Cons
Aptamers DNA and/or RNA aptamers bind to







protein isoforms and different
conformational forms of the
same protein





occupy the active site of target
demonstrating functional
pharmacology and leading to





Often nonspecific for their target of
interest/might be limited by rapid
metabolism, poor cell membrane




Expression of inactive mutant
forms of target protein form
oligomers with WT protein
in vivo, reducing their activity




Applicable on essential proteins/
high specificity
Unable to provide complete
knockout effect/Structural
information of the target is
needed
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aptamers and conditional knockout/down elements to enable
conditional control of target candidates translation in an efficient
manner [93,94].
While aptamers recognize their targets with binding specifici-
ties and affinities comparable to those of monoclonal antibodies,
the use of the first method possesses multiple advantages over
the second one, including lower susceptibility to contamination
and no limitation to highly immunogenic targets. Moreover, the
small size of aptamers enables them to reach smaller compart-
ments and cells, for which antibody penetration is limited. In terms
of efficiency, aptamers require less production time (one to three
months) than antibodies (four to six months). As a major disad-
vantage, aptamers are susceptible to degradation by nucleases. To
minimize this problem, chemical modifications or molecules such
as polyethylene glycol (PEG) and biotin can be added to their 3ʹ
and 5ʹ ends to prevent degradation [109].
2.3.2. Small molecule inhibitor probes
Validating targets using pharmacological agents often works
in conjunction with computational approaches to leverage
the desired high selectivity of chemical probes [15]. Small
molecule-targeting-probes must be able to bind the active
site, demonstrate functional pharmacology and ultimately
lead to a desired phenotypic effect [14]. Many essential
proteins of P. falciparum, such as cytochrome bc1 and dihy-
drofolate reductase (DHFR), have been chemically validated.
Inhibitors blocking the activity of the latter are of particular
interest, as they exploit the folate synthesis pathway, an
essential metabolic pathway for the parasite DNA replication
process [111]. Dihydroorotate dehydrogenase (DHODH), an
essential mitochondrial target enzyme of the de novo pyr-
imidine biosynthesis pathway was recently validated with
small-molecule probes [112]. Specific DHODH inhibitors,
such as the compound DSM265, demonstrated IC50 values
of 40–80nM against P. falciparum and extremely high speci-
ficity for the parasite DHODH over human DHODH [113,114].
Target inhibition by the use of small molecules has also an
important role in target deconvolution. As previously men-
tioned, the identification of resistance mutations selected by
the presence of known inhibitors with non-identified targets
has the potential to reveal mechanisms of action that can then
be targeted by novel antimalarial drugs [26,75,115,116].
But despite the widespread use of chemical probes, their
application is still open to confirmational bias as small mole-
cules are often nonspecific for their target of interest
[117,118]. In addition, rapid metabolism, poor cell membrane
passage and subcellular location after successful entry are still
potential disadvantages of chemical probes [15,118].
2.3.3. Oligomerisation interference-based validation
Protein oligomerisation is the self-assembly of more than one
copy of a single or different protein(s) into one functional
complex [119,120]. Currently, about 60% of all protein struc-
tures available in the Protein Data Bank (PDB) are oligomers;
dimers been the majority of this class [11,12]. Indeed, oligo-
merisation is a common feature shared by proteins of all
biological systems, and interestingly present in key enzymes
of the plasmodial pyrimidine biosynthesis (e.g. orotate phos-
phoribosyltransferase, OPRT; orotidine 5ʹ-phosphate
decarboxylase, ODCase), aspartate metabolism (aspartate ami-
notransferase, AspAT and aspartate transcarbamoylase, ATC),
vitamin B6 biosynthesis (pseudo enzyme, Pdx1.2) and malate
metabolism (malate dehydrogenase, MDH) among other car-
bon metabolism pathways [9,121]. The oligomeric Protein
Interference Assay (PIA), our recently proposed validation
technique, takes advantage of oligomerization by disrupting
oligomeric interfaces using mutant subunits of the target
candidates and causing a significant reduction in specific
enzyme activity [10,122] (Figure 3(b,c)). The biomechanics of
the assembly of oligomer subunits and evolution of oligomeric
interfaces make PIA remarkably interesting. Protein oligomer-
isation has been observed to influence the correct active site
or cofactor binding pocket conformation for many proteins,
consequently playing an important role in their activity
[120,123]. In some cases, residues from different subunits
contribute to form the active-site [124,125]. Therefore, inter-
ference with a nonfunctional subunit might have a significant
effect on the biological activity of these enzymes, as pre-
viously demonstrated [124,125].
A recent study was carried out targeting two key-enzymes
of the aspartate metabolism pathway, aspartate aminotransfer-
ase (PfAspAT, Figure 4) and malate dehydrogenase (PfMDH,
Figure 5) [122]. Multiple factors led to PfAspAT and PfMDH to
be considered good candidates for the application of PIA
based-inhibition for the first time: both enzymes present
a low degree of conservation for the residues that form the
oligomeric interfaces, unlike the residues that compose the
active-site [122,124] and both possess their active sites formed
across the interface between 2 monomers, and thus are
dependent on their oligomeric state to be fully active
[124,126]. Subsequently, in vitro experiments have demon-
strated that the introduction of mutations on the oligomeric
surfaces can impair the function of these enzymes and the
mutant forms of both enzymes can form oligomers with the
wild-type forms, also impairing their function [122]. In short,
endogenous expression of mutant forms of both these
enzymes in transfected parasites demonstrated that, although
the introduction of AspAT and MDH mutants alone did not
result in significant effect on parasite proliferation in blood-
stage cultures, the transfection of parasites with both plasmids
resulted in a significant reduction in parasite proliferation in
aspartate-limited media (used to mimic physiological condi-
tions) [122]. Aspartate is known to be the least common of all
the amino acids available within the human serum, with mea-
surements suggesting a concentration of < 20 µM [127].
Although aspartate is available in hemoglobin, which is used
as a source of amino acids (except isoleucine) during the blood
stage [128], the PIA experiments on AspAT and MDH enzymes
suggest insufficiency of this source to support the rapid pro-
liferation of the parasite. Therefore, a functional, aspartate
biosynthesis is likely to be a key element for the maintenance
of P. falciparum in human red blood cells. These data not only
validate the aspartate metabolism as an essential pathway in
P. falciparum but also fully support the hypothesis that oligo-
meric surfaces offer a highly promising opportunity to specifi-
cally influence protein behavior in Plasmodium in vitro cultures.
Oligomerisation has the advantage of being highly selec-
tive. The evolutionally diverse and large surface area of
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Figure 3. Schematic representation of protein-based validation techniques applied to Plasmodium. (a) SELEX methodology. After incubation of the aptamer library
with culture or lysate of parasites, unbound nucleic acids are separated from bound ones. Nucleic acid-protein complexes are then dissociated and the nucleic acid
pool is amplified and enriched. The new generated nucleic acid pool serves as a starting library for a new SELEX cycle composed of identical steps as the first round.
The number of SELEX repetition depends on the library type used and on specific enrichment achieved per a selection cycle. After the last round of aptamer
selection, the PCR products are cloned and sequenced [107,108]. (b) and (c) Overview of two independent strategies for the use of Protein Interference Assay (PIA) in
Plasmodium. In the first, the transfection of parasites with a construct encoding for a copy of the target gene containing one or more inactivating mutations on the
oligomeric interface leads to endogenous expression of this mutant. The formation of oligomeric complexes between the native active protein and the mutant
protein results in inactive heterocomplexes, leading to a knockdown effect at protein level. In the second, clashing mutation(s) are introduced to one oligomeric
interface while other(s) oligomeric interface(s) is preserved. The endogenous expression of the mutant allows for heterocomplex formation with the native protein,
preventing the formation of the full oligomeric complex. The presence of the cashing mutation in at least one monomer leads to inactivation of proteins which
function depend on the oligomeric state, thus, resulting in a knockdown effect [10,122].
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oligomeric interfaces ensures unusual selectivity of subunits
for each other, minimizing cross-reactivity [123]. Oligomeric
surfaces of homologous proteins are, in many cases, signifi-
cantly less conserved compared to their substrates’ active sites
and/or cofactor binding pockets [119,123]. In the validation of
essentiality of target candidates, this high specificity and selec-
tivity offer an important advantage, for instance, over the use
of small-molecule-based validation proteomic tools. The most
noticeable disadvantage of this approach is the inability to
provide a complete knockout effect since the heterocomplex
formation is unlikely to effect all wild-type subunits. The level
of inhibition also seems to vary from protein to protein. As an
example, specific activity measurements in whole-cell lysates
demonstrated an approximately 2-fold inhibition for AspAT-
mutant culture compared to control culture, while the MDH
mutant showed a slight decrease that did not reach statistical
significance when compared to control culture [122].
Furthermore, the design of a PIA experiment requires struc-
tural information in order to identify key residues that can
induce the desired phenotypic effect.
3. Conclusion
The antimalarial validation toolbox is currently filled with several
genetic and proteomic-based tools that can report on
a protein’s biological activity. However, knockout and knock-
down systems are often highly complex or difficult to perform,
time-consuming, too costly or are simply not effective for essen-
tial genes of the parasite. Moreover, small molecule inhibitor-
based tools are often nonspecific and do not always yield the
Figure 4. (a) The dimeric structure of plasmodial aspartate aminotransferase (PfAspAT). (b) and (c) The oligomeric interface of the WT-PfAspAT dimer. Residues Tyr68
and Arg257 from both subunits are shown in sticks[122].
Figure 5. Mutations designed for the protein interference assay (PIA) approach targeting plasmodial malate dehydrogenase (PfMDH). (a) The tetrameric structure of
PfMDH, the different subunits are labeled A-D. (b) The A-B interface of the wild-type (WT)-PfMDH tetramer. Residues Glu118 from both subunits are shown in sticks.
(c) The steric clash generated by the introduction of a Tryptophan in position 118. The mutant monomer is shown in green and WT monomer is shown in yellow. (d)
A-C interface of WT-PfMDH tetramer. Residues Val190 from both subunits are shown in sticks. (e) The steric clash generated by the introduction of a tryptophan in
position 190. The mutant monomer is shown in green and WT monomer is shown in magenta [122,124].
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desired efficacy partly owing to the complex nature of the
parasite’s life cycle [8]. These and many other challenges with
the current toolset highlight the need for novel specific valida-
tion alternatives. The validation of P. falciparum aspartate meta-
bolism essentiality through the recently developed PIA
methodology reinforces the need to revisit the validation pro-
cesses of targets where conventional validations tools failed.
4. Expert opinion
Possessing a good repertoire of genetic manipulative tools in
assessing the role of a gene’s product is a must in drug discov-
ery. In this review, the reader was introduced to the currently
used validation methods in malaria. As discussed above, despite
the particular advantages of genetic techniques, the overall
difficulty of applying these methods to essential genes represent
a significant drawback for their use as validation methods. In this
scenario, conditional and inducible validation tools are of great
value. These methods indeed represent a better alternative for
validation of essential genes/proteins, but neither of them is
applicable to all classes of proteins, all species of Plasmodium
or possess full efficacy in disturbing/degrading the target. With
proteomic approaches, a significant advantage is the ability to
assess targets with different functional isoforms with further
post-translationally variations, but poor specificity for their target
of interest, rapid metabolism, poor cell membrane passage/pen-
tration and subcellular localization after successful entry are still
significant barriers. In this scenario, we introduce the concept of
the oligomeric Protein Interference Assay (PIA), a highly specific
method to control biological activity by disrupting oligomeric
interfaces using mutant subunits of the target protein. Via this
method, it is possible to achieve a significant reduction in spe-
cific enzyme activity in in vitro cultures, as demonstrated for the
enzymes PfAspAT and PfMDH. Moreover, the previously
reported phenotypic effect of the introduction of these mutant
subunits within the parasite supported the validation of the
aspartate metabolism from P. falciparum as an essential pathway
without recourse to complex genetic approaches.
It is important to stress that the PIA approach does not
represent a replacement for other validation techniques
applied to malaria. As other methods, PIA possesses limita-
tions, the most noticeable being the inability to provide
a complete knockout effect. Instead of being used as
a single definitive method, PIA can be combined with other
validation methods to provide a more complete understand-
ing of the assessed target. PIA also represents a powerful
method to validate the essentiality of metabolic pathways
instead of single targets. When different components are
assessed in parallel, as demonstrated for AspAT/MDH, the
negative effect in parasites’ growth is much more pronounced.
An important addition to the setup of PIA experiments could
be represented by the use of bioinformatic tools. Molecular
modeling could potentially suppress the need for structural
information for some targets. Furthermore, these tools could
potentially be used in the development of a pipeline able to
identify residues that, if mutated, would cause the desired effect.
Although our report on the PIA approach is, so far, limited to
two enzymes of P. falciparum [122], the successful assessment of
these targets suggests a broader potential for this technique. In
principle, the two main requirements for the application of PIA to
a specific target are structure information and oligomerization.
The constant addition of crystallographic structures to the protein
data bank, added to the fact that more than 60% of the structures
currently deposited there are reported in an non-monomeric
oligomeric state support the hypothesis that the PIA approach
can be applied not only to more metabolic pathway within
P. falciparum but also extrapolated to other infectious diseases.
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